What is the appropriate management for a 31‑year‑old bedridden woman with serum calcium 7.1 mg/dL, albumin 4.2 g/dL, alkaline phosphatase 3528 U/L, and 25‑hydroxy‑vitamin D 9 ng/mL?

Management of Severe Hypocalcemia with Vitamin D Deficiency in a Bedridden Patient

This 31-year-old bedridden woman requires immediate treatment for life-threatening hypocalcemia (7.1 mg/dL with normal albumin) secondary to severe vitamin D deficiency (9 ng/mL), with markedly elevated alkaline phosphatase (3528 U/L) indicating severe secondary hyperparathyroidism and likely osteomalacia.

Immediate Management (First 24-48 Hours)

Hospitalize immediately given the calcium level below 7.5 mg/dL, which meets criteria for life-threatening hypocalcemia requiring IV calcium therapy 1.

IV Calcium Administration

• Start with calcium gluconate bolus: 1-2 grams (90-180 mg elemental calcium) IV over 10-20 minutes with continuous cardiac monitoring 1
• Check EKG immediately for QTc prolongation (>0.47 seconds in women indicates cardiac risk) 1
• Monitor for: cardiac arrhythmias, laryngospasm, bronchospasm, seizures, or tetany during infusion 1

Continuous IV Infusion

• Mix 10 grams calcium gluconate (900 mg elemental calcium) in 1 liter D5W or normal saline
• Start at 100 mL/hour and titrate based on calcium levels 1
• Do NOT add bicarbonate or phosphate to the solution (forms insoluble calcium salts) 1
• Monitor ionized or albumin-corrected calcium every 6 hours initially, then daily until stable 1

Concurrent Oral Therapy (Start Immediately)

• Calcium carbonate: 1500-2000 mg elemental calcium daily, divided 3-4 times daily 1
• Calcitriol: 0.5-1.0 μg twice daily (or alfacalcidol 1.0-1.5 μg once daily) 1

Critical Considerations for This Patient

The Bedridden Status is Crucial

Reduce active vitamin D doses in immobilized patients to prevent hypercalciuria and hypercalcemia 2. Once calcium normalizes, consider using lower maintenance doses of calcitriol (0.25-0.5 μg twice daily) given her immobility.

The Markedly Elevated Alkaline Phosphatase (3528 U/L)

This extreme elevation with severe vitamin D deficiency (9 ng/mL) indicates:

• Severe osteomalacia with defective bone mineralization 3, 4, 5
• Florid secondary hyperparathyroidism from chronic vitamin D deficiency
• High bone turnover state that amplifies hypocalcemia severity 3

The combination of severe hypocalcemia, profound vitamin D deficiency, and markedly elevated ALP in a bedridden patient suggests "hungry bone syndrome" physiology where rapid bone remineralization will occur once treatment begins, potentially requiring sustained high-dose calcium supplementation 3.

Vitamin D Repletion Strategy

Loading Phase (Weeks 1-8)

Given severe deficiency (9 ng/mL) and immobility:

• Vitamin D3 50,000 IU weekly for 8 weeks 6
• Alternative: 6,000 IU daily for 8 weeks 6
• Goal: achieve 25(OH)D >30 ng/mL 6

Maintenance Phase (After Week 8)

• 3,000-6,000 IU daily long-term given bedridden status and likely ongoing limited sun exposure 6
• Bedridden patients have higher requirements due to lack of cutaneous vitamin D synthesis

Monitoring Protocol

First Week

• Albumin-corrected or ionized calcium every 6 hours while on IV calcium, then daily 1
• Serum phosphorus, magnesium daily 1
• EKG if symptomatic or calcium remains <7.5 mg/dL 1

Weeks 2-12

• Calcium, phosphorus, magnesium, creatinine weekly 1
• 25(OH)D at 3 months to assess repletion 1
• PTH at 3 months (expect gradual normalization) 1
• 24-hour urine calcium monthly once calcium normalizes—critical in bedridden patients to detect hypercalciuria (target <250 mg/24h for women) 1

Long-term (Every 3-6 Months)

• Calcium, phosphorus, magnesium, creatinine 1
• 25(OH)D every 6-12 months (maintain >30 ng/mL) 1
• Annual renal ultrasound to screen for nephrocalcinosis given immobility risk 1

Expected Clinical Course

Calcium Normalization

• Target low-normal range (8.0-8.5 mg/dL) initially to avoid overshooting 1
• Transition from IV to oral therapy when calcium >7.5 mg/dL and patient tolerating oral intake 1
• May require several weeks of high-dose calcium supplementation due to hungry bone physiology 3

Alkaline Phosphatase

• Will remain elevated for months as osteomalacia heals 3, 4, 5
• Gradual decline indicates successful bone remineralization
• Persistent elevation beyond 6 months warrants bone density assessment

PTH Normalization

• Expect gradual decline over 3-6 months as vitamin D stores replete 4, 5
• Persistent elevation suggests inadequate vitamin D repletion or ongoing calcium/vitamin D malabsorption

Critical Pitfalls to Avoid

1. Rapid IV calcium infusion causes cardiac arrest—always infuse over 10-20 minutes with monitoring 1

2. Stopping calcium too early—bedridden patients with severe osteomalacia develop hungry bone syndrome requiring prolonged high-dose calcium (often 3-6 months) 3

3. Excessive active vitamin D in immobile patients—causes hypercalciuria, nephrocalcinosis, and renal stones 1, 2. Monitor 24-hour urine calcium closely.

4. Missing hypomagnesemia—hypocalcemia will not correct without magnesium repletion 1

5. Inadequate vitamin D dosing—severe deficiency (9 ng/mL) requires aggressive repletion with 50,000 IU weekly, not standard doses 6

6. Overlooking underlying cause of immobility—address why she is bedridden, as this perpetuates vitamin D deficiency and bone loss

Investigate Underlying Etiology

While treating, evaluate for:

• Malabsorption disorders (celiac disease, inflammatory bowel disease) given severe vitamin D deficiency 7, 6
• Dietary history—severe malnutrition can cause this presentation 4, 5
• Reason for bedridden state—neurologic, psychiatric, or musculoskeletal causes
• Medication review—anticonvulsants, glucocorticoids increase vitamin D requirements 6

If patient fails to respond to standard vitamin D dosing, consider celiac disease or cystic fibrosis workup 6.